Does tumor mutational status correlate with clinical response to imatinib? Commentary

Michael C. Heinrich; Christopher L. Corless

doi:10.1038/ncponc0639

Does tumor mutational status correlate with clinical response to imatinib? Commentary

Michael C. Heinrich, Christopher L. Corless

Knight Cancer Institute

Research output: Contribution to journal › Short survey › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	600-601
Number of pages	2
Journal	Nature Clinical Practice Oncology
Volume	3
Issue number	11
DOIs	https://doi.org/10.1038/ncponc0639
State	Published - Nov 2006

ASJC Scopus subject areas

Oncology

Access to Document

10.1038/ncponc0639

Cite this

@article{c48074e341be4535b564127b2637f6aa,

title = "Does tumor mutational status correlate with clinical response to imatinib? Commentary",

author = "Heinrich, {Michael C.} and Corless, {Christopher L.}",

year = "2006",

month = nov,

doi = "10.1038/ncponc0639",

language = "English (US)",

volume = "3",

pages = "600--601",

journal = "Nature Clinical Practice Oncology",

issn = "1743-4254",

publisher = "Nature Publishing Group",

number = "11",

}

TY - JOUR

T1 - Does tumor mutational status correlate with clinical response to imatinib? Commentary

AU - Heinrich, Michael C.

AU - Corless, Christopher L.

PY - 2006/11

Y1 - 2006/11

UR - http://www.scopus.com/inward/record.url?scp=33750555557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750555557&partnerID=8YFLogxK

U2 - 10.1038/ncponc0639

DO - 10.1038/ncponc0639

M3 - Short survey

C2 - 17080176

AN - SCOPUS:33750555557

SN - 1743-4254

VL - 3

SP - 600

EP - 601

JO - Nature Clinical Practice Oncology

JF - Nature Clinical Practice Oncology

IS - 11

ER -

Does tumor mutational status correlate with clinical response to imatinib? Commentary

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this